Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANIRELIX ACETATE vs PREGNYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART),Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
FDA: Treatment of prepubertal cryptorchidism,FDA: Induction of ovulation and pregnancy in anovulatory infertile women,Off-label: Hypogonadotropic hypogonadism in males,Off-label: Assisted reproductive technology (ART) protocols
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.
Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.
Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing.
Terminal elimination half-life: 23–24 hours; clinically, supports daily or every-other-day dosing; peak effect may lag due to prolonged absorption
Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement.
Primarily renal metabolism and excretion; limited hepatic metabolism.
Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%).
Renal: 10-20% as unchanged drug; hepatic metabolism to inactive metabolites; fecal excretion negligible (<5%)
Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein.
~80% bound primarily to albumin; minor binding to sex hormone-binding globulin (SHBG)
Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding.
0.5–0.7 L/kg; moderately distributed into extracellular fluid; penetrates gonadal tissues
Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection.
Intramuscular: ~100%; Subcutaneous: comparable (~95-100%); Oral: <5% (not used)
No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (Cr Cl < 30 m L/min).
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment.
Not approved for use in pediatric patients.
Not indicated for prepubertal children; for delayed puberty in males: 1,000-2,000 IU intramuscularly 2-3 times weekly for 3-6 months.
Not approved for use in geriatric patients.
No specific recommendations; use lowest effective dose due to potential increased sensitivity and comorbidities.
None
No FDA black box warning.
Hypersensitivity reactions (urticaria, angioedema) have been reported,Ovarian hyperstimulation syndrome (OHSS) may occur with ART,Congenital abnormalities cannot be excluded; pregnancy should be excluded before use
Ovarian hyperstimulation syndrome (OHSS) in women,Arterial thromboembolism,Precocious puberty in males,Fluid retention,Ovarian enlargement or cyst rupture
Hypersensitivity to ganirelix or any component,Known or suspected pregnancy,Lactation (not recommended due to potential neonatal effects)
Hypersensitivity to h CG or any component,Premature epiphyseal closure in males,Androgen-dependent neoplasia (e.g., prostate cancer),Undiagnosed uterine bleeding,Ovarian cyst or enlargement due to polycystic ovarian syndrome (PCOS),Active thromboembolic disorders
No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised.
No known clinically significant food interactions. Maintain usual diet unless advised otherwise by physician.
Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption.
Pregny (h CG) is not indicated for use during pregnancy. h CG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnormalities, but human data are insufficient. First trimester: No direct fetal risk from therapeutic use as it is discontinued before implantation. Second/Third trimester: Not used. Overall, classified as FDA Pregnancy Category X for ovulation induction (contraindicated in pregnancy) but no teratogenic risk if discontinued before conception.
Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible.
Human chorionic gonadotropin (h CG) is normally present in breast milk in low concentrations. Exogenous h CG is likely excreted into breast milk, but the M/P ratio is not established. Due to lack of data and potential for adverse effects in the infant (e.g., hormonal disruption), breastfeeding is not recommended during therapy. The manufacturer advises discontinuing breastfeeding or avoiding the drug.
No dose adjustments in pregnancy; contraindicated. If inadvertently used, discontinue immediately; no study on pharmacokinetic changes in pregnancy.
Pregny is contraindicated in pregnancy. No dose adjustment is applicable as it is discontinued prior to conception. There are no pharmacokinetic data for pregnancy, but the drug is not used during gestation.
Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment.
Pregnyl (h CG) is used to trigger final follicular maturation and ovulation in assisted reproduction. Monitor for ovarian hyperstimulation syndrome (OHSS); consider withholding h CG if estradiol >4000 pg/m L or >20 follicles per ovary. Administer exactly 36 hours before oocyte retrieval. Intramuscular injection into gluteal muscle; rotate sites if repeated doses.
Inject exactly as prescribed, typically once daily during the stimulation phase.,Do not skip doses; missed doses may reduce effectiveness.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately.,Store at room temperature (20-25°C) and protect from light.,Use within 30 days after first use.
Use Pregnyl exactly as prescribed to trigger ovulation; timing is critical for egg retrieval.,Report severe pelvic pain, bloating, nausea, or rapid weight gain (possible OHSS) immediately.,Avoid pregnancy tests during treatment as h CG may cause false positive.,May cause injection site pain or swelling; apply warm compress if needed.,Do not discontinue without consulting your fertility specialist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANIRELIX ACETATE vs PREGNYL, answered by our medical review team.
GANIRELIX ACETATE is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. PREGNYL is a Gonadotropin Hormone that works by Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANIRELIX ACETATE and PREGNYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANIRELIX ACETATE is: 250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.. The standard adult dose of PREGNYL is: Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANIRELIX ACETATE and PREGNYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANIRELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) . PREGNYL is classified as Category C. Pregny (hCG) is not indicated for use during pregnancy. hCG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.